$AN2 Therapeutics (ANTX.US)$ AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline Thursday, 1st May at 4:00 pm EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease Extensive enabling NTM data provides potential path forward in M. abscessus lung disease Co...
3
Report
Yueling5
:
Master Jaguar, can check CDTG as the share drop more than 70%. worth to buy it?
Jaguar8
OPYueling5
:
I stay away from China stocks without real catalyst unless you know how to scalp. They are good at pumping and dumping likw rhis one
$AN2 Therapeutics (ANTX.US)$It will be risky if it cannot climb on $1.9~2.0 in the next week. But anyway, promising. Hopefully they really have some positive results.
$AN2 Therapeutics (ANTX.US)$Reuters· 1 min ago AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (Caused by Mycobacterium Tuberculosis) and Malaria
1
Report
Trytosaveabit
OP
:
Grant from the Bill & Melinda Gates Foundation
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
AN2 Therapeutics Stock Forum
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Thursday, 1st May at 4:00 pm
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease
Extensive enabling NTM data provides potential path forward in M. abscessus lung disease
Co...
AN2 Therapeutics Extends Cash Runway to 2027, Reveals Key Phase 3 Timeline Updates
Can AN2's Strategic Pivot Save Its MAC Lung Disease Treatment? Phase 2 Data Offers Hope
I am in here for swing play. Chart looks good and insiders have been loading.
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (Caused by Mycobacterium Tuberculosis) and Malaria
No comment yet